Literature DB >> 25228381

Gene silencing of non-obese diabetic receptor family (NLRP3) protects against the sepsis-induced hyper-bile acidaemia in a rat model.

Y Wu1, J Ren, B Zhou, C Ding, J Chen, G Wang, G Gu, X Wu, S Liu, D Hu, J Li.   

Abstract

The role of NOD-like receptor family (NLRP3) has been confirmed in various inflammatory diseases. The association between NLRP3 and hyper-bileacidaemia during the sepsis remains unclear. We aimed to investigate whether NLRP3 silencing protects against the sepsis-induced hyper-bileacidaemia. Sepsis was induced by caecum ligation and puncture (CLP). Gene silencing of NLRP3 was performed by injecting rats with NLRP3 short hairpin RNA plasmids (NLRP3 shRNA) 48 h before surgery. Rats were divided into four groups: group 1: sham; group 2: sepsis; group 3: NLRP3 shRNA + sepsis (called the 'NLRP3 shRNA' group); and group 4: scrambled shRNA + sepsis (called the 'scrambled shRNA' group). The serum levels of bile acids, hepatic expression of hepatocyte membrane transporters, hepatic cytokine levels and behaviours of immune cells were compared among the groups. Hepatic NLRP3 expression was increased dramatically during the sepsis, but was suppressed by pretreatment with NLRP3 shRNA. Compared with rats in the sepsis and the scrambled shRNA groups, rats in the NLRP3 shRNA group exhibited significantly decreased serum levels of glycine and taurine conjugated-bile acids, with rehabilitated expression of hepatocyte transporters, suppressed hepatic cytokine levels, decreased hepatic neutrophils infiltration and attenuated macrophages pyroptosis. Gene silencing of NLRP3 ameliorates sepsis-induced hyper-bileacidaemia by rehabilitating hepatocyte transporter expression, reducing hepatic cytokine levels, neutrophil infiltration and macrophages pyroptosis. NLRP3 may be a pivotal target for sepsis management.
© 2014 British Society for Immunology.

Entities:  

Keywords:  NLRP3 inflammasome; hyper-bileacidaemia; liver injury; sepsis

Mesh:

Substances:

Year:  2015        PMID: 25228381      PMCID: PMC4298405          DOI: 10.1111/cei.12457

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

Review 1.  Molecular aspects of hepatobiliary transport.

Authors:  M Müller; P L Jansen
Journal:  Am J Physiol       Date:  1997-06

2.  Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver.

Authors:  Michal Ganz; Timea Csak; Bharath Nath; Gyongyi Szabo
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

3.  Intravascular danger signals guide neutrophils to sites of sterile inflammation.

Authors:  Braedon McDonald; Keir Pittman; Gustavo B Menezes; Simon A Hirota; Ingrid Slaba; Christopher C M Waterhouse; Paul L Beck; Daniel A Muruve; Paul Kubes
Journal:  Science       Date:  2010-10-15       Impact factor: 47.728

4.  Increased survival and reduced neutrophil infiltration of the liver in Rab27a- but not Munc13-4-deficient mice in lipopolysaccharide-induced systemic inflammation.

Authors:  Jennifer L Johnson; Hong Hong; Jlenia Monfregola; Sergio D Catz
Journal:  Infect Immun       Date:  2011-07-11       Impact factor: 3.441

5.  Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression.

Authors:  Yoo-Mee Vanwijngaerden; Joost Wauters; Lies Langouche; Sarah Vander Perre; Christopher Liddle; Sally Coulter; Sara Vanderborght; Tania Roskams; Alexander Wilmer; Greet Van den Berghe; Dieter Mesotten
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 6.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation.

Authors:  Sanjeev Mariathasan; Denise M Monack
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

7.  Electron-microscopic demonstration of multidrug resistance protein 2 (Mrp2) retrieval from the canalicular membrane in response to hyperosmolarity and lipopolysaccharide.

Authors:  F Dombrowski; R Kubitz; A Chittattu; M Wettstein; N Saha; D Häussinger
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

Review 8.  The role of liver sinusoidal cells in hepatocyte-directed gene transfer.

Authors:  Frank Jacobs; Eddie Wisse; Bart De Geest
Journal:  Am J Pathol       Date:  2009-11-30       Impact factor: 4.307

9.  Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis.

Authors:  Andreas Geier; Christoph G Dietrich; Sebastian Voigt; Suk-Kyum Kim; Thomas Gerloff; Gerd A Kullak-Ublick; Johann Lorenzen; Siegfried Matern; Carsten Gartung
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  11 in total

1.  Magnesium protects against sepsis by blocking gasdermin D N-terminal-induced pyroptosis.

Authors:  Dingyu Wang; Jiashuo Zheng; Qiongyuan Hu; Cheng Zhao; Qianyue Chen; Peiliang Shi; Qin Chen; Yujie Zou; Dayuan Zou; Qiyao Liu; Jingwen Pei; Xiuwen Wu; Xiang Gao; Jianan Ren; Zhaoyu Lin
Journal:  Cell Death Differ       Date:  2019-06-17       Impact factor: 15.828

2.  TLR4 regulates vascular smooth muscle cell proliferation in hypertension via modulation of the NLRP3 inflammasome.

Authors:  Hui-Meng Qi; Qin Cao; Qiang Liu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

3.  Deletion of Nlrp3 Augments Survival during Polymicrobial Sepsis by Decreasing Autophagy and Enhancing Phagocytosis.

Authors:  Liliang Jin; Sanjay Batra; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2016-12-28       Impact factor: 5.422

Review 4.  The NLRP3 Inflammasome and Its Role in Sepsis Development.

Authors:  Lucinéia Gainski Danielski; Amanda Della Giustina; Sandra Bonfante; Tatiana Barichello; Fabricia Petronilho
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

5.  Role of Thymoquinone in Cardiac Damage Caused by Sepsis from BALB/c Mice.

Authors:  Hongyang Liu; Yan Sun; Ying Zhang; Guang Yang; Lipeng Guo; Yue Zhao; Zuowei Pei
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

6.  Intermedin1-53 Protects Cardiac Fibroblasts by Inhibiting NLRP3 Inflammasome Activation During Sepsis.

Authors:  Di Wu; Lin Shi; Pengyang Li; Xianqiang Ni; Jinsheng Zhang; Qing Zhu; Yongfen Qi; Bin Wang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 7.  Recent Advances in the Molecular Mechanisms Underlying Pyroptosis in Sepsis.

Authors:  Yu-Lei Gao; Jian-Hua Zhai; Yan-Fen Chai
Journal:  Mediators Inflamm       Date:  2018-03-07       Impact factor: 4.711

8.  Hydrogen alleviates mitochondrial dysfunction and organ damage via autophagy‑mediated NLRP3 inflammasome inactivation in sepsis.

Authors:  Hongguang Chen; Xing Mao; Xiaoyin Meng; Yuan Li; Jingcheng Feng; Linlin Zhang; Yang Zhang; Yaoqi Wang; Yonghao Yu; Keliang Xie
Journal:  Int J Mol Med       Date:  2019-08-13       Impact factor: 4.101

9.  A Novel Mechanism of Mesenchymal Stromal Cell-Mediated Protection against Sepsis: Restricting Inflammasome Activation in Macrophages by Increasing Mitophagy and Decreasing Mitochondrial ROS.

Authors:  Shuang Li; Hao Wu; Dong Han; Sai Ma; Wensi Fan; Yabin Wang; Ran Zhang; Miaomiao Fan; Yuesheng Huang; Xiaobing Fu; Feng Cao
Journal:  Oxid Med Cell Longev       Date:  2018-02-13       Impact factor: 6.543

10.  NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension.

Authors:  Hai-Jian Sun; Xing-Sheng Ren; Xiao-Qing Xiong; Yun-Zhi Chen; Ming-Xia Zhao; Jue-Jin Wang; Ye-Bo Zhou; Ying Han; Qi Chen; Yue-Hua Li; Yu-Ming Kang; Guo-Qing Zhu
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.